Home › Trial NCT01678417
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
- Trial IDNCT01678417
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorKorea Cancer Center Hospital
- Enrollment29
- Start date2012-06
- ConditionsRelapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.